This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Dr. Matthew Engelhard and Anivarya Kumar In this Friday’s PCT Grand Rounds, Matthew Engelhard and Anivarya Kumar of Duke University will present “A Cross-Sectional Study of GPT-4Based Plain Language Translation of Clinical Notes to Improve Patient Comprehension of Disease Course and Management.” The Grand Rounds session will be held on Friday, March 28, 2025, at 1:00 pm eastern.
Investigators at Mass General Brigham have uncovered how resistance to chemotherapies may occur in some cancers. Researchers focused on a pathway that harnesses reactive oxygen species (ROS) to kill cancer cells. The study found that mutations to VPS35, a key player in this pathway, can prevent chemotherapy-induced cell death. These results, published in Nature, could help pinpoint treatment-resistant tumors.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
After a strong showing in 2024, leading packaged foods company BBB Foods saw their stocks rise from $17.50 to over $28 per share, followed by a successful secondary offering this year. Moreover, Guzman y Gomezs, a renowned Australian fast-casual chain known for a fresh, made-to-order Mexican food experience, whose shares surged 37% on debut, now has its very first location in Illinois.
By Adrienne R. Lenz, Principal Medical Device Regulation Expert Last year, FDA issued a letter to the medical device industry warning medical device firms of concerns related to fraudulent and unreliable laboratory testing data in premarket submissions, which we blogged about here. This was followed last September with warning letters issued to two Chinese firms performing biocompatibility testing, citing violations of 21 C.F.R.
Roughly one out of three women ages 14-49 in the United States develop a vaginal bacterial imbalance known as bacterial vaginosis (BV) during their lifetime. BV is characterized by unpleasant odors, and potentially painful side effects, as well as the risk of associated health issues later in life. More than half of the patients who seek medical care do not respond to the first-line treatment, the antibiotic metronidazole, leading to recurrence.
Purple Day 2025, celebrated on March 26, has set sail with the theme Power In Purple, honoring the strength and resilience of individuals living with epilepsy. Organized in collaboration between the Epilepsy Foundation and The Anita Kaufmann Foundation, this years Purple Day highlights the importance of solidarity, visibility and education. Epilepsy is characterized by recurrent, unprovoked seizures caused by irregular brain activity.
Artificial intelligence (AI) is no longer a futuristic concept in healthcareits here, embedded in nearly every touchpoint of modern pharma marketing. From generative AI tools that draft emails to predictive algorithms that segment target audiences, the speed and scale of innovation are staggering. But as pharma marketers race to adopt these tools, a central question looms: Is AI fueling smarter engagement, or setting the stage for a compliance disaster?
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal the verdict, a strategy successfully employed by Eisai.
According to a recent study from the University of Jyvskyl, Finland, the impacts of everyday physical activity do not attenuate the accelerated hormonal bone loss that occurs during menopause. Effective bone-loading impacts are rare in everyday life. Future research should explore whether more targeted exercise can slow menopausal bone loss. The study suggests that impacts accumulated during everyday life are not sufficient to slow hormonal bone loss during menopause.
The Unseen Hurdles of Generic Drug Development: Lessons Learned As the pharmaceutical industry continues to evolve, one thing remains constant: the pursuit of affordable, high-quality medications for patients worldwide. Generic drugs have long been a vital part of this equation, offering a more accessible alternative to brand-name medications. However, the journey to bringing a generic drug to market is often fraught with challenges.
This is the latest episode of the free DDW narrated podcast, titled Innovation enabled by new drug discovery technologies, which covers two articles written for DDW Volume 24 Issue 3, Summer 2023. They are called: CRISPR breakthroughs: New solutions for common diseases and Re-assessing the risks of drug-induced arrhythmias during drug discovery .
The company plans to file next year for an accelerated clearance of its "exon-skipping" treatment, which would compete with one of Sarepta's medicines.
Researchers from Auburn University, in a landmark collaboration with Brazil's Oswaldo Cruz Foundation (FIOCRUZ), the world's leading research institution on Chagas Disease, have published a significant study in the journal Biochemistry. The study sheds new light on how the Chagas Disease parasite invades human cellsa crucial step towards developing effective treatments for this neglected tropical disease.
In the fast-evolving field of clinical research, thought leaders do more than just keep up; they lead the charge and shape the direction of the industry. True thought leadership is achieved by consistently providing valuable insights, challenging the status quo and offering innovative solutions that address the fields most pressing challenges. Businesses that establish themselves as trusted voices not only gain credibility but also attract key partnerships and position themselves as pioneers.
In what is believed to be a world-first study, researchers from the University of Adelaide's Australian Dysautonomia and Arrhythmia Research Collaborative (ADARC) have used brain scans to identify blood flow problems in people with postural orthostatic tachycardia syndrome (POTS).
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Alopecia is an autoimmune disorder that causes non-scarring hair loss on the scalp and body that is experienced by almost 2% of the global population at some point in their lifetime.
Spring has officially arrived in sunny downtown Philadelphiathe proud home base of Drug Channels. As you can see on the right, we celebrated in Miami at the Drug Channels Leadership Forum. The vernal equinox also brought a surprising surge of industry updates and noteworthy news you wont want to miss: Blue Shield of California provides a puzzling update to its PBM unbundling effort The Stelara biosimilar price war begins My reaction to Optum Rxs pharmacy reimbursement announcement A valuable Fol
A research study conducted by The Journal of Commerce and FourKites surveyed hundreds of international shippers, exploring how their usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19. For international shippers, ocean freight visibility has evolved from optional to essential and satisfaction with visibility varies greatly depending on how it is obtained and delivered.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
157 
Let's personalize your content